"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 3 | 7 | 10 |
| 1998 | 2 | 4 | 6 |
| 1999 | 2 | 8 | 10 |
| 2000 | 2 | 11 | 13 |
| 2001 | 3 | 11 | 14 |
| 2002 | 8 | 5 | 13 |
| 2003 | 6 | 11 | 17 |
| 2004 | 12 | 14 | 26 |
| 2005 | 13 | 10 | 23 |
| 2006 | 16 | 13 | 29 |
| 2007 | 13 | 14 | 27 |
| 2008 | 23 | 17 | 40 |
| 2009 | 21 | 25 | 46 |
| 2010 | 13 | 20 | 33 |
| 2011 | 25 | 29 | 54 |
| 2012 | 30 | 18 | 48 |
| 2013 | 27 | 30 | 57 |
| 2014 | 17 | 24 | 41 |
| 2015 | 31 | 31 | 62 |
| 2016 | 22 | 34 | 56 |
| 2017 | 30 | 29 | 59 |
| 2018 | 31 | 35 | 66 |
| 2019 | 51 | 31 | 82 |
| 2020 | 43 | 27 | 70 |
| 2021 | 25 | 34 | 59 |
| 2022 | 2 | 27 | 29 |
| 2023 | 0 | 19 | 19 |
| 2024 | 18 | 37 | 55 |
| 2025 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Oncologist. 2025 Feb 06; 30(2).
-
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.
-
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. Nat Commun. 2025 Jan 02; 16(1):32.
-
Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review. JAMA Oncol. 2025 Jan 01; 11(1):60-69.
-
DEK :: AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma : A Clinical Outcome Study Compared With Conventional Sinonasal Squamous Cell Carcinoma. Am J Surg Pathol. 2025 Feb 01; 49(2):130-137.
-
Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor. J Clin Endocrinol Metab. 2024 Dec 18; 110(1):263-274.
-
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2025 Feb; 209(3):563-572.
-
Exploring the potential of TGFß as a diagnostic marker and therapeutic target against cancer. Biochem Pharmacol. 2025 Jan; 231:116646.
-
Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1/TSC2-Mutations: A Series of 4 cases and a review of the literature. Hum Pathol. 2024 Nov; 153:105680.
-
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.